- 104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion
- Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027
- First-in-class PRS inhibitor being developed as a potential new therapeutic option for IPF
BARCELONA, Spain and SEOUL, South Korea, Sept. 24, 2026 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented a poster on the baseline characteristics of all 104 patients enrolled in the global Phase 2 clinical trial of its idiopathic pulmonary fibrosis (IPF) drug candidate 'Bersiporocin (DWN12088)' at the European Respiratory Society (ERS) Congress 2026, held on September 6 (local time) in Barcelona, Spain.
Idiopathic Pulmonary Fibrosis is a disease in which various inflammatory and fibrotic signals interact, leading to excessive production and accumulation of collagen. Bersiporocin, being developed by Daewoong Pharmaceutical, selectively inhibits prolyl-tRNA synthetase (PRS), thereby reducing excessive collagen production associated with fibrosis.
Bersiporocin has a differentiated mechanism of action that targets collagen synthesis downstream of multiple profibrotic signals through PRS inhibition. Based on this distinct mechanism, it is being evaluated both in patients receiving background antifibrotic therapy and in those not receiving such treatment.
This presentation analyzed the baseline clinical and functional characteristics of all IPF patients recruited in South Korea and the United States. Following the presentation of interim enrollment data at KATRDIC 2025, Daewoong Pharmaceutical presented baseline data from the fully enrolled study population for the first time at ERS 2026.
The analysis showed that of the total 104 patients, 55 (52.9%) were from South Korea and 49 (47.1%) from the US. A total of 71 patients (68.3%) were receiving background antifibrotic therapy, while 33 patients (31.7%) were not. Mean forced vital capacity (FVC) was approximately 77% predicted, while mean diffusing capacity of the lungs for carbon monoxide (DLCO) was approximately 51% predicted. Overall, baseline clinical and functional characteristics were generally similar between patients with and without background antifibrotic therapy.
The ongoing global Phase 2 study is a randomized, double-blind, placebo-controlled trial taking place in South Korea and the US. Patients receive either Bersiporocin or a placebo twice daily for 24 weeks, with concomitant use of pirfenidone or nintedanib permitted. The study design reflects real-world IPF treatment settings by including patients both with and without background antifibrotic therapy.
This baseline analysis provides important context for interpreting the Phase 2 efficacy and safety results. Daewoong Pharmaceutical plans to announce top-line Phase 2 results in the first half of 2027.
Meanwhile, Bersiporocin has received Orphan Drug Designation and Fast Track status from the US FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA), driving its global development forward.
Professor Moo Suk Park of the Department of Pulmonology at Severance Hospital, who participated in the study, said, "This study provides a comprehensive overview of the baseline characteristics of 104 IPF patients enrolled in South Korea and the US. As the study includes patients both with and without background antifibrotic therapy, these baseline data will provide important context for interpreting the efficacy and safety outcomes of Bersiporocin."
Seongsoo Park, CEO of Daewoong Pharmaceutical, stated, "Successfully completing enrollment for the global Phase 2 trial and sharing the full baseline patient profile at ERS 2026 marks a significant milestone in Bersiporocin's development. We will continue to advance the program toward top-line Phase 2 results in H1 2027 and use these findings to inform subsequent global development."
[Reference]
https://drive.google.com/file/d/1XSXImvc5mcgdoSozP_B4BnDlsTW7Pfz_/view
Link to the poster: 'Baseline Clinical and Functional Spectrum of Idiopathic Pulmonary Fibrosis Patients in a Fully Enrolled Global Phase 2 Trial of the PRS Inhibitor Bersiporocin'
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
SUBANG JAYA, Malaysia, Sept. 24, 2026 /PRNewswire/ -- Lion Parcel, a leading Indonesia-based logistics service provider, officially opened its first international office in Subang Jaya, Malaysia, marking its first step into an international market and strengthening logistics connectivity between Malaysia, Indonesia, and beyond.
Malaysia was selected as the first market for Lion Parcel's international expansion due to its strategic position as a regional hub. Through its presence, Lion Parcel aims to create more opportunities for businesses and communities to meet their cross-border delivery needs, connecting Malaysia with Indonesia and other international markets.
"Malaysia is an important first step in Lion Parcel's international journey. We see significant opportunities to optimize the Lion Group ecosystem, particularly Batik Air Malaysia's air connectivity. This provides Lion Parcel's business partners with access to a wider international network. In addition, the cargo infrastructure supported by Batik Air Malaysia's Cargo Terminal Operator (CTO) further strengthens Lion Parcel's operational infrastructure, enabling more efficient processes so that packages can be delivered faster and more securely," said Farian Kirana, Chief Executive Officer of Lion Parcel.
Farian added, "With this foundation, we want to provide businesses and communities with broader access to logistics connectivity, helping them move goods more efficiently across markets and reach wider opportunities. That is why we want to be present not only as a logistics service provider, but also as an enabler within the ecosystem, connecting businesses to more possibilities as they grow."
Echoing this view, Alvin Williams, Country Head of Lion Parcel Malaysia, said the company sees Malaysia not only as an important market, but also as a strategic location within the region's evolving logistics landscape.
"Malaysia has an important role to play in the development of regional logistics connectivity, particularly with Kuala Lumpur International Airport (KLIA) continuing to develop its position as a regional air cargo and transshipment hub. For us, this creates opportunities to connect logistics services with the wider air cargo network and support the movement of goods between Malaysia, Indonesia and other international markets," said Alvin.
Building on this connectivity, Lion Parcel Malaysia aims to complement the existing air and cargo infrastructure by connecting delivery services to the wider logistics network. Lion Parcel Malaysia currently provides delivery services for both B2B and retail customers, covering international shipments to destinations served through the Lion Group's flight network.
Powered by the Lion Group Ecosystem
Lion Parcel's presence in Malaysia is supported by the Lion Group ecosystem, including air connectivity through Batik Air Malaysia, which currently serves over 60 destinations across 20 countries, spanning key markets across Southeast Asia, China, India, Australia and other regional destinations. Lion Parcel will leverage this network as part of its operational development, while expanding delivery connectivity between Malaysia, Indonesia, and other international markets.
Lion Parcel is also supported by a Cargo Terminal Operator (CTO) operated by Batik Air Malaysia, strategically located at KLIA Cargo Village, Selangor, Malaysia. This integrated cargo infrastructure serves as a key differentiator for Lion Parcel, helping to accelerate the delivery process through air freight while supporting safer and more efficient international deliveries.
As its first international market, Malaysia marks the beginning of Lion Parcel's broader international journey, with the company continuing to explore opportunities to expand its connectivity and collaborate with partners across markets.
For more information about Lion Parcel Malaysia, please visit https://lionparcel.com/my.
About Lion Parcel
Lion Parcel is an Indonesia-based logistics company. Established in 2013, Lion Parcel provides integrated logistics solutions covering first-mile, middle-mile, and last-mile services for both domestic and international deliveries. As it continues to develop its infrastructure and network, Lion Parcel has officially opened its first international office in Subang Jaya, Malaysia, in 2026.
Supported by the Lion Group ecosystem, an aviation group with operations across various countries in Southeast Asia, Lion Parcel has built a logistics network connecting businesses and communities in Indonesia with international markets. Today, Lion Parcel's services reach up to 99% of Indonesia and more than 50 countries across five continents. Supported by thousands of agents, delivery couriers, logistics fleets, and access to hundreds of Lion Group aircraft, Lion Parcel is committed to continuously strengthening logistics connectivity without limitations of time and distance, while providing services that are affordable, safe, and reliable.
Find out more about Lion Parcel here https://lionparcel.com/.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Lion Parcel Officially Expands to Malaysia, Marking Its First Step into International Expansion
